Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower
Aug 05
Swedish (OMX) Biotech Industry Analysis
UpdatedAug 05, 2024
DataAggregated Company Financials
Companies64
- 7D-2.4%
- 3M2.9%
- 1Y18.0%
- YTD2.7%
Over the last 7 days, the Biotech industry has dropped 2.4%, driven by Swedish Orphan Biovitrum declining 8.0%. On the other hand BioArctic is actually up 9.1%. In the past year, the industry has gained 18%. Looking forward, earnings are forecast to grow by 47% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 05 Aug 2024 | SEK 194.1b | SEK 31.4b | -SEK 5,420,171,537.87 | 43.2x | -35.8x | 6.2x |
| Wed, 03 Jul 2024 | SEK 198.1b | SEK 30.6b | -SEK 5,537,955,895.65 | 38.9x | -35.8x | 6.5x |
| Fri, 31 May 2024 | SEK 190.9b | SEK 30.6b | -SEK 5,521,375,815.02 | 38.9x | -34.6x | 6.2x |
| Sun, 28 Apr 2024 | SEK 183.9b | SEK 30.8b | -SEK 5,612,153,350.26 | 50.9x | -32.8x | 6x |
| Tue, 26 Mar 2024 | SEK 184.9b | SEK 29.8b | -SEK 5,637,322,776.64 | 59x | -32.8x | 6.2x |
| Thu, 22 Feb 2024 | SEK 181.4b | SEK 29.8b | -SEK 5,695,797,699.32 | 51.1x | -31.8x | 6.1x |
| Sat, 20 Jan 2024 | SEK 186.9b | SEK 28.7b | -SEK 1,200,602,862.00 | 57.4x | -155.6x | 6.5x |
| Mon, 18 Dec 2023 | SEK 181.1b | SEK 28.7b | -SEK 1,170,293,890.00 | 60.4x | -154.7x | 6.3x |
| Wed, 15 Nov 2023 | SEK 165.8b | SEK 28.7b | -SEK 1,234,398,551.00 | 52.5x | -134.3x | 5.8x |
| Fri, 13 Oct 2023 | SEK 157.0b | SEK 27.4b | -SEK 1,998,260,805.00 | 48.4x | -78.5x | 5.7x |
| Sun, 10 Sep 2023 | SEK 150.4b | SEK 27.4b | -SEK 1,977,547,540.00 | 47x | -76.1x | 5.5x |
| Tue, 08 Aug 2023 | SEK 153.6b | SEK 27.5b | -SEK 1,574,655,024.00 | 53.9x | -97.6x | 5.6x |
| Thu, 06 Jul 2023 | SEK 162.6b | SEK 26.4b | -SEK 1,284,080,487.00 | 46.1x | -126.7x | 6.2x |
| Sat, 03 Jun 2023 | SEK 168.1b | SEK 26.4b | -SEK 1,240,134,651.00 | 45.5x | -135.6x | 6.4x |
| Mon, 01 May 2023 | SEK 175.8b | SEK 26.3b | -SEK 1,262,253,450.00 | 45.6x | -139.3x | 6.7x |
| Wed, 29 Mar 2023 | SEK 163.2b | SEK 25.4b | -SEK 2,015,466,531.00 | 38.5x | -81x | 6.4x |
| Fri, 24 Feb 2023 | SEK 170.8b | SEK 25.4b | -SEK 2,116,388,881.00 | 38.4x | -80.7x | 6.7x |
| Sun, 22 Jan 2023 | SEK 176.8b | SEK 23.8b | -SEK 1,839,311,016.00 | 32.2x | -96.1x | 7.4x |
| Tue, 20 Dec 2022 | SEK 159.4b | SEK 23.8b | -SEK 1,838,079,007.00 | 31.3x | -86.7x | 6.7x |
| Thu, 17 Nov 2022 | SEK 160.0b | SEK 23.9b | -SEK 1,903,388,533.00 | 32.2x | -84x | 6.7x |
| Sat, 15 Oct 2022 | SEK 153.0b | SEK 22.9b | -SEK 3,333,771,163.00 | 31.2x | -45.9x | 6.7x |
| Mon, 12 Sep 2022 | SEK 159.5b | SEK 22.9b | -SEK 3,243,830,491.00 | 34x | -49.2x | 7x |
| Wed, 10 Aug 2022 | SEK 168.4b | SEK 22.7b | -SEK 3,505,608,071.00 | 36.2x | -48x | 7.4x |
| Fri, 08 Jul 2022 | SEK 162.3b | SEK 21.4b | -SEK 3,520,398,720.00 | 37.5x | -46.1x | 7.6x |
| Sun, 05 Jun 2022 | SEK 158.7b | SEK 21.4b | -SEK 3,525,318,201.00 | 44.4x | -45x | 7.4x |
| Tue, 03 May 2022 | SEK 151.9b | SEK 21.3b | -SEK 3,486,721,975.00 | 45.1x | -43.6x | 7.1x |
| Thu, 31 Mar 2022 | SEK 171.0b | SEK 19.7b | -SEK 3,133,717,785.00 | 50.8x | -54.6x | 8.7x |
| Sat, 26 Feb 2022 | SEK 153.9b | SEK 19.6b | -SEK 2,694,708,673.00 | 48.4x | -57.1x | 7.9x |
| Mon, 24 Jan 2022 | SEK 168.7b | SEK 19.1b | -SEK 2,041,717,712.00 | 50.4x | -82.6x | 8.8x |
| Wed, 22 Dec 2021 | SEK 192.7b | SEK 19.0b | -SEK 1,992,777,823.00 | 51.8x | -96.7x | 10.1x |
| Fri, 19 Nov 2021 | SEK 202.8b | SEK 19.0b | -SEK 1,412,764,251.00 | 55x | -143.5x | 10.7x |
| Sun, 17 Oct 2021 | SEK 200.0b | SEK 18.1b | -SEK 1,345,754,716.00 | 47.3x | -148.7x | 11.1x |
| Tue, 14 Sep 2021 | SEK 219.6b | SEK 18.1b | -SEK 1,339,275,285.95 | 56x | -164x | 12.1x |
| Thu, 12 Aug 2021 | SEK 193.2b | SEK 18.1b | -SEK 1,175,418,285.95 | 54x | -164.4x | 10.7x |
Price to Earnings Ratio
-164.4x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 6.2x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 20% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -4.26% | |
| Healthcare | -3.15% | |
| Biotech | -2.36% | |
| Biotech | -2.36% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BIOA B BioArctic | SEK 159.00 | 1.1% +SEK 159.0m | -46.2% | PS55.7x | |
| ISOFOL Isofol Medical | SEK 2.32 | 19.0% +SEK 59.8m | 269.4% | PB3.3x | |
| ALZ Alzinova | SEK 3.88 | 50.4% +SEK 57.9m | 14.0% | PS9.6x | |
| DMYD B Diamyd Medical | SEK 17.62 | 2.7% +SEK 45.9m | 83.5% | PS9497.9x | |
| LIPUM Lipum | SEK 12.00 | 12.1% +SEK 27.6m | 34.5% | PS4802.8x |
